Wall Street : Wells Fargo Upgrades to Outperform $94 PT.
Analysts: PC Decline Hurts Microsoft’s Outlook and 2 Other Research Notes To Look Into
By Justin Lloyd-Miller | More Articles
April 19, 2013
Page 2 of 3view all
Vertex (NASDAQ:VRTX): After positive results from Vertex’s Pase II trial of the Kalydeco/VX-661 combo treatment for cystic fibrosis, Wells Fargo maintains that the data should improve the risk profile of the company’s entire cystic fibrosis franchise. The firm raised its valuation on the shares to $94, up from $62-$64, and maintains an Outperform rating.